Aromatase Inhibitors in Risk Reduction of Breast Cancer: Potential Use in Premenopausal Women

Česká verzia

Authors: P. Kubatka; M. Péč
Authors place of work: Ústav lekárskej biológie, Jesseniova LF UK, Martin, Slovenská republika
Published in the journal: Klin Onkol 2009; 22(6): 268-272
Category: Reviews

Summary

Aromatase inhibitors are effective and well tolerated drugs in the endocrine therapy of estrogen‑ receptor positive breast cancer in postmenopausal women. Questions remain about the long‑term side effects and safety profile of aromatase inhibitors. The results of ongoing studies may indicate the role of aromatase inhibitors in the prevention of breast cancer. The effectiveness and safety of aromatase inhibitor monotherapy in premenopausal breast cancer patients is unknown, so this is an area of future exploration. Our results in the chemoprevention of mammary carcinogenesis in female rats pointed to the potential favourable effects of aromatase inhibitors – anastrozole and letrozole in premenopausal women affected by breast cancer.

Key words:
aromatase inhibitors – breast cancer – premenopause – risk reduction

Zdroje

1. Paridaens R, Therasse P, Dirix L et al. First‑line hormonal treatment (HT) for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients – A randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 2004; 22: 14.

2. Mouridsen H, Sun Y, Gershanovich M et al. Superiority of letrozole to tamoxifen in the first‑line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 2004; 9: 489– 496.

3. Thürlimann B, Hess D, Koberle D et al. Anastrozole (‘Arimidex’) versus tamoxifen as first‑line therapy in postmenopausal women with advanced breast cancer: Results of the double‑blind cross‑ over SAKK trial 21/ 95 – a sub‑study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85: 247– 254.

4. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081– 1092.

5. Thürlimann BJ, Keshaviah A, Mouridsen H et al. BIG 1– 98: randomized double‑blind phase III study to evaluate letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor‑ positive breast cancer. Proc Am Soc Clin Oncol 2005; 23: 16.

6. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‑stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analysis. Cancer 2003; 98: 1802– 1810.

7. Howell A, Cuzick J, Baum M et al. (ATAC Trialists’ Group). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60– 62.

8. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor‑ positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262– 1271.

9. Santen RJ, Yue W, Naftolin F et al. The potential of aromatase inhibitors in breast cancer prevention. Endocr Rel Cancer 1999; 6: 235– 243.

10. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19: 881– 894.

11. Freedman OC, Verma S, Clemons MJ. Pre‑menopusal breast cancer and aromatase inhibitors: treating a new generation of women. Breast Cancer Res Treat 2006; 99: 241– 247.

12. Santen RJ, Martel J, Hoagland F et al. Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 1994; 79: 627– 632.

13. Bernstein LM, Larionov AA, Kyshtoobaeva AS et al. Aromatase in breast cancer tissue localization and relationship with reproductive status of patients. J Cancer Res Clin Oncol 1996; 122: 495– 498.

14. Yue W, Wang JP, Hamilton CJ et al. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 1998; 58: 927– 932.

15. Kubatka P, Sadloňová V, Kajo K et al. Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis. Neoplasma 2008; 55: 42– 46.

16. Kubatka P, Sadloňová V, Kajo K et al. Chemopreventive effects of anastrozole in a premenopausal breast cancer model. Anticancer Res 2008; 28: 2819– 2823.

17. Santen RJ, Samojlik E, Wells SA. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 1980; 51: 473– 477.

18. Bulun SE, Sharda G, Rink J et al. Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J Clin Endocrinol Metab 1996; 91: 1273– 1277.

19. Wysowski DK, Comstock GW, Helsing KJ et al. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987; 125: 791– 799.

20. Berrino F, Muti P, Micheli A et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996; 88: 291– 296.

21. Roche HH, Thierry D, Chieze S et al. Anastrozole and goserelin combination as first treatment for premenopausal receptor positive advanced or metastatic breast cancer: A phase II trial. J Clin Oncol 2009; 27 (15 Suppl): 1079.

22. Li HZ, Chen XN, Qiao J. Letrozole as primary therapy for endometrial hyperplasia in young women. Int J Gyn Obst 2008; 100: 10– 12.

23. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fert Steril 2006; 85: 1307– 1318.

24. Cortinez A, De Carvalho I, Vantman D et al. Hormonal profile and endometrial morphology in letrozole‑ controlled ovarian hyperstimulation in ovulatory infertile patients. Fert Steril 2005; 83: 110– 115.

25. Fentiman IS. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors. Int J Clin Pract 2006; 60: 689– 693.

26. Geisler J. Breast cancer tissue estrogens and their manipulations with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 2003; 86: 245– 253.

27. Thijssen JH. Local biosynthesis and metabolism of oestrogens in the human breast. Maturitas 2004; 49: 25– 33.

28. Miller WR, Stuart M, Sahmoud T et al. Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. Br J Cancer 2002; 87: 950– 955.

29. Geisler J, Detre S, Berntsen H et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001; 7: 1230– 1236.

30. Esteban JM, Warsi Z, Haniu M et al. Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am J Pathol 1992; 140: 337– 343.

31. Sadloňova V, Kubatka P, Kajo K. Side effects of anastrozole in the experimental pre‑menopausal mammary carcinogenesis. Neoplasma 2009; 56: 124– 129.

32. Iino Y, Karakida T, Sugamata N et al. Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12- dimethylbenz(a)anthracene‑induced mammary tumors in rats. Anticancer Res 1998; 18: 171– 176.

33. Kumru S, Yildiz AA, Yilmaz B et al. Effects of aromatase inhibitors letrozole and anastrozole on bone metabolism and steroid hormone levels in intact female rats. Gyn Endocrinol 2007; 23: 556– 561.

34. Iveson TJ, Smith IE, Ahern J et al. 1993 Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993; 77: 316– 318.

35. Dowsett M, Stein RC, Mehta A et al. Potency and selectivity of the non‑steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol 1990; 32: 623– 634.

36. Kendall A, Dowsett M. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. End Rel Cancer 2006; 13: 827– 837.

37. Jannuzzo MG, Di Salle E, Spinelli R et al. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat 2009; 113: 491– 499.

38. Dowsett M, Haynes BP. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Bioch Mol Biol 2003; 86: 255– 263.